诚达药业：前海晟泰拟减持7.27%股份

Group 1 - The major shareholder Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership) plans to reduce its stake in Chengda Pharmaceutical from September 29, 2025, to December 28, 2025 [1] - The planned reduction involves selling up to 11.0069 million shares, which represents 7.27% of the company's total share capital after excluding repurchased shares [1] - The selling price will be determined based on market conditions [1]